Multiple Class I Peptides & Montanide ISA 51 VG w Escalating Doses of Anti-PD-1 ab BMS936558

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.

ClinicalTrials.gov Identifier: NCT01176461

Recruitment Status : Active, not recruiting

First Posted : August 6, 2010

Last Update Posted : April 21, 2021

Sponsor:

Collaborators:

National Cancer Institute (NCI)

Bristol-Myers Squibb

Medarex

Information provided by (Responsible Party):

H. Lee Moffitt Cancer Center and Research Institute

No Study Results Posted on ClinicalTrials.gov for this Study

About Study Results Reporting on ClinicalTrials.gov

Recruitment Status :	Active, not recruiting
Actual Primary Completion Date :	December 12, 2016
Estimated Study Completion Date :	December 2021

Publications automatically indexed to this study by ClinicalTrials.gov Identifier (NCT Number):

Weber JS, Kudchadkar RR, Yu B, Gallenstein D, Horak CE, Inzunza HD, Zhao X, Martinez AJ, Wang W, Gibney G, Kroeger J, Eysmans C, Sarnaik AA, Chen YA. Safety, efficacy, and biomarkers of nivolumab with vaccine in ipilimumab-refractory or -naive melanoma. J Clin Oncol. 2013 Dec 1;31(34):4311-8. doi: 10.1200/JCO.2013.51.4802. Epub 2013 Oct 21.

To Top